Abbott Laboratories
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1.6% | -1.0% | +0.8% | +1.8% | +9.5% | +0.0% | +3.1% | +0.2% | +3.0% | +27.3% | -1.1% | |
| – | +0.0% | -1.3% | +3.3% | +3.0% | -0.6% | -2.1% | +5.7% | +1.5% | +4.7% | -1.9% | -3.9% | |
| – | +2.8% | -8.9% | +11.2% | +8.2% | +0.8% | -14.2% | +6.4% | +8.1% | +13.5% | -20.2% | -25.0% | |
| – | +3.3% | -8.6% | +8.5% | +7.9% | +2.3% | -14.1% | +6.4% | +6.2% | +15.6% | -18.4% | -23.2% | |
| – | +1.0% | +0.6% | +3.8% | +2.9% | -1.8% | +5.8% | +8.8% | +2.1% | -2.6% | +3.5% | +4.7% | |
| – | -1.2% | +3.9% | -0.2% | 0.0% | -9.1% | +7.2% | +4.7% | -3.5% | -3.3% | +7.7% | +4.7% | |
| – | – | – | – | – | +0.3% | +2.6% | +4.2% | +1.0% | +2.7% | – | – | |
| – | +1.7% | -1.3% | -0.3% | +1.5% | -2.3% | +1.1% | +2.5% | +0.1% | +0.3% | +46.5% | +0.1% | |
| – | -5.0% | -5.9% | -5.7% | -6.1% | -9.6% | -5.8% | -5.4% | -5.4% | -1.3% | +223.5% | -3.7% | |
| – | 0.0% | -2.8% | +0.1% | +2.6% | -2.4% | -3.4% | +2.4% | -0.8% | +3.1% | +70.1% | -0.5% | |
| – | +6.1% | +1.3% | -1.9% | +8.3% | -5.0% | -8.1% | +3.3% | +8.5% | +13.1% | +11.4% | -3.1% | |
| – | +26.1% | +51.7% | -19.7% | +33.4% | -18.6% | -71.2% | +0.2% | +165.3% | +146.0% | +33.2% | -31.8% | |
| – | +8.4% | -2.7% | -1.3% | -2.2% | +4.0% | +0.5% | +2.2% | -4.2% | +2.8% | +10.4% | +2.5% | |
| – | -6.1% | -7.5% | +4.5% | -2.4% | -1.6% | +0.9% | +1.5% | -10.3% | -14.7% | +199.5% | – | |
| – | +3.0% | +0.5% | +1.3% | +1.2% | +19.8% | +2.4% | +3.6% | +0.8% | +2.3% | -0.1% | -1.8% | |
| – | +1.7% | +1.2% | +0.9% | +1.8% | +21.0% | +1.0% | +1.6% | +1.3% | +1.4% | +0.4% | -0.3% | |
| – | 0.0% | +0.1% | +0.1% | -0.2% | -0.1% | +0.1% | +0.2% | -0.1% | -0.1% | +0.0% | -0.2% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.